Antineoplaston Therapy in Treating Patients With Ependymoma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Antineoplaston Therapy in Treating Patients With Ependymoma (NCT00003479), a na phase 2 study. The primary outcome is Number of Participants With Objective Response.

2. Clinical Question

The stated purpose was to determine the effects, both good and bad, of antineoplaston therapy in patients with ependymoma. In a single-group study, the observed outcomes describe participants who received the intervention, but there is no concurrent untreated or alternative-treatment group to provide a direct comparison. As a result, the study can address whether responses or adverse events were recorded among participants, but it cannot by itself establish how those outcomes compare with what would have happened under another treatment or without this intervention.

The registry record identifies survival as a secondary outcome, but does not report a survival result. It also does not report details such as the enrollment criteria, disease characteristics, or other treatments participants may have received. Those omissions limit how specifically the study population and clinical context can be characterized.

3. Trial Design

This was a phase II, single-group study of antineoplaston therapy in patients with ependymoma. The registry lists an enrollment of 9 and identifies Burzynski Research Institute as the sponsor. Allocation is recorded as not applicable, and masking is recorded as none. The study status is terminated. The registry lists a start date of 1966-07 and a primary completion date of 2000-10.

Participants received Atengenal and Astugenal by intravenous infusion every four hours for at least 12 months. The dose was increased until the maximum tolerated dose was reached. The record does not report additional details about dose levels, dose-adjustment decisions, adherence, or reasons for stopping treatment. It also does not report the reason the study was terminated.

The design has no concurrent comparator. Consequently, response and safety observations can be described for the treated group, but differences between treatment strategies cannot be estimated from this study. The lack of masking also means the registry does not describe a blinded assessment process. The record does not report whether imaging was reviewed independently or whether outcome assessors were otherwise kept unaware of treatment or clinical information.

The primary outcome is the number of participants with objective response at 12 months, with response assessed by MRI using Response Assessment in Neuro-Oncology criteria for target lesions. Percentage of participants who survived is listed as a secondary outcome. The registry record lists no analysis results. The protocol’s statistical analysis plan, any interim analyses, and the rationale for the planned enrollment are not reported in the registry record.

These design features matter when interpreting the outcome information. A single-group study can provide descriptive observations, but those observations do not separate treatment effects from the course of disease, participant selection, or other influences. Because the response result itself is not reported in the registry record, even a descriptive estimate of the primary endpoint cannot be assessed from the posted record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Objective Response, measured over 12 months.

The primary endpoint is the number of participants with an objective response at 12 months. Response is assessed by MRI for target lesions using Response Assessment in Neuro-Oncology criteria. The record describes complete response as disappearance of all disease sustained for at least four weeks. Partial response is defined as a decrease of at least 50% in the sum of products of perpendicular diameters of measurable enhancing lesions, sustained for at least four weeks. Stable disease and progressive disease are defined using specified changes in lesion measurements and minimum durations.

In general, an objective-response endpoint is used to describe whether measurable lesions meet prespecified criteria for improvement. Using defined imaging criteria gives a structured way to classify changes rather than relying only on an overall impression. The duration requirements in the registry definitions also distinguish a sustained classification from a shorter-lived change.

The endpoint is reported as a participant count, not as a time-to-event measure. However, the registry record does not report how many participants met the response criteria, how many were assessed, or how missing or unevaluable scans were handled. Without those results, the endpoint definition can be described, but the response outcome cannot be interpreted quantitatively.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The available design information supports a descriptive interpretation rather than a controlled comparison. The registry identifies the study as single group, with allocation not applicable and no masking. In general, a single-group study measures outcomes among participants receiving the intervention. Because there is no concurrent comparator, it cannot isolate the intervention’s effect from other influences on outcomes. A response observed in the group is an observation in that group, not a difference between treatment strategies.

What does a participant count communicate?

The primary endpoint is a count of participants meeting the objective-response definition at 12 months. In general, a count is an absolute description of the number of people who met a criterion. To interpret a count as a rate or proportion, the assessed population and denominator also need to be clear. The registry record does not report the response count, the number assessed for response, or how incomplete assessment was handled. The enrollment figure alone does not establish how many participants contributed evaluable imaging at the endpoint.

The outcome definition uses MRI measurements for target lesions and assigns categories based on lesion changes sustained for specified durations. Complete and partial response describe reductions or disappearance meeting the stated criteria; stable disease and progressive disease describe other patterns of change. In general, prespecified thresholds can help make outcome classification more consistent. They do not, by themselves, show that the imaging was reviewed consistently or that assessors were blinded. Those operational details are not reported in the registry record.

Why does the single-group design matter?

In a randomized comparative study, treatment groups can be compared under a design intended to balance participant characteristics. This record does not describe randomization or a comparator. A before-and-after or historical comparison is not reported either. Thus, there is no treatment contrast from which to estimate a comparative effect. Even if the primary count were available, it would describe observed response in the study group and could not establish what response would have been under an alternative approach.

Masking is listed as none. In general, masking can reduce the influence of expectations on some aspects of care, outcome assessment, or reporting. The registry’s masking field does not establish whether particular procedures were independently reviewed or standardized. The record does not report additional measures to limit assessment bias.

What can be learned from the safety counts?

The registry gives participants at risk and affected counts separately for serious and other adverse events. These are descriptive summaries. In general, an event count does not identify whether the event was caused by the intervention, and participants may experience more than one event. The record does not provide event-level timing, duration, recurrence, severity grading, or attribution details. The listed serious-event terms and their percentages should therefore be read as reported safety information, not as a causal comparison or a complete account of all harms.

General statistical interpretation of event summaries also depends on the definition of the analysis population and the period during which events were collected. The registry record does not explain those details. It does not report whether safety follow-up continued after treatment stopped, how missing safety information was handled, or whether event coding and review were performed using a stated plan.

What does the record say about statistical testing?

No analysis results are listed. The statistical plan, any hypothesis tests, confidence intervals, adjustments, or interim analyses are not reported in the registry record. Without an analysis result, there is no p-value or interval estimate for the primary outcome to interpret. In general, a confidence interval expresses the range of estimates compatible with the observed data under a specified method; it does not fix weaknesses in study design or replace a comparator.

The record includes assumptions for planning illustrations: a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. These are planning assumptions, not an analysis of participants in this single-group study. The assumptions do not supply an observed response effect, and the registry record does not report the result needed to interpret such illustrations as trial-specific evidence. Any sample-size figures based on these assumptions are planning illustrations, not observed power or trial findings.

Over-dispersion is a general concern when outcome variation exceeds what a statistical model assumes; if present, it can make uncertainty estimates too narrow. The registry record does not report a dispersion estimate or model for the primary outcome. Since the endpoint result and analysis are missing, there is no basis for assessing whether a particular model was used or whether its assumptions were checked.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists an objective-response endpoint and a secondary outcome of percentage of participants who survived. It does not report results for either outcome. It also does not report a prespecified hierarchy of endpoints, a multiplicity adjustment, or how any repeated assessments or analyses were handled. The statistical analysis plan is not reported in the registry record, so it is not possible to determine whether the listed outcomes represent the full set considered or how formal statistical testing, if any, was planned.

In general, testing multiple outcomes or repeatedly examining data can increase the chance of finding an apparently notable result by chance. A prespecified analysis plan can clarify which outcomes are primary, how comparisons are controlled, and how results are selected for reporting. Those details are not reported in the registry record. Because no analyses are listed, there are no posted p-values or confidence intervals to interpret in the context of multiplicity.

The registry record does not report missing-data methods, an analysis population, the number assessed at the primary endpoint, or how participants who stopped treatment or did not have evaluable imaging were classified. It also does not say whether the primary analysis included all enrolled participants or only participants with an available assessment. These omissions prevent evaluation of how incomplete follow-up might affect the response result.

In general, missing outcome information can matter when the likelihood of missingness is related to disease status, treatment tolerability, or other participant characteristics. The record does not provide enough detail to assess whether that concern arose in this study or how it was addressed. The listed enrollment should not be treated as the denominator for an unreported endpoint without confirmation from the analysis record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: hemoglobin (11.1%), central venous catheter infection (11.1%), rash: erythema multiforme (11.1%), pancreatitis (11.1%), infection (documented clinically): blood (11.1%).

The registry separates serious adverse events from other adverse events for the antineoplaston therapy group. For serious events, 9 participants are listed as at risk and 5 as affected. For other adverse events, 9 are listed as at risk and 9 as affected. These are participant counts in the registry record. They should not be added together: serious and other event categories are presented separately, and the record does not establish whether the same participant experienced events in both categories.

The listed serious-event terms are Hemoglobin, Central venous catheter infection, Rash: erythema multiforme, Pancreatitis, Infection (documented clinically): Blood, and Hypokalemia. Each is reported with a percentage of 11.1%. The registry record does not give further detail about the timing, duration, severity grading, recurrence, or treatment attribution for these terms. It also does not explain whether the list includes every serious event or only terms meeting a reporting threshold.

In general, adverse-event summaries describe events observed during a defined reporting period; they do not by themselves show that treatment caused an event. The lack of a comparator means these figures cannot be used to estimate an excess risk relative to another treatment. The registry record does not report the safety-analysis population or the duration of safety follow-up, so the counts should be understood as the reported summaries rather than a complete causal assessment.

12. What the Result Does, and Does Not, Mean

The registry record establishes that a phase II study of antineoplaston therapy in patients with ependymoma was conducted as a single-group study and is now listed as terminated. It describes the primary endpoint, an MRI-based objective-response assessment at 12 months, and reports safety counts for the treatment group. It does not report the observed response count, survival result, or statistical analyses. The central efficacy question therefore cannot be answered from the posted results.

The record does not show that no response occurred, nor does it show that a response occurred. A missing outcome result is not equivalent to a result of zero. Similarly, the listed safety counts do not demonstrate that treatment caused the events, and they cannot establish how those counts compare with another treatment because no comparator group is described.

In general, a treatment effect is most directly assessed by comparing outcomes between appropriately designed groups. This study’s single-group design cannot provide that controlled comparison. Even if the response count were reported, the absence of a comparator would leave uncertainty about how outcomes might have differed under another approach. The posted record also lacks the analysis methods and information about endpoint assessment needed to evaluate precision and potential bias.

The result is thus a limited registry record of study design, endpoint definitions, and adverse-event summaries rather than a report of interpretable efficacy estimates. The enrollment figure describes the study’s recorded enrollment, not the number with a complete primary endpoint assessment. The registry does not report enough information to characterize missingness, follow-up, or the analysis population.

These distinctions are important for readers assessing clinical evidence. A trial’s stated purpose and outcome definitions describe what it set out to examine; they are not outcome findings. The status of terminated does not, on its own, explain why the study ended or what conclusions its investigators reached. The reason for termination and any final investigator interpretation are not reported in the registry record.

13. Why This Trial Matters Statistically

This study illustrates why registry design fields and outcome reporting need to be read separately. The record identifies the clinical population, intervention, endpoint definition, study status, and safety summaries. But without a reported primary outcome result, readers cannot estimate objective response or assess its precision. Stating an endpoint and defining how it is measured are not substitutes for reporting what was observed.

The single-group design is also central to the statistical interpretation. Descriptive outcomes can document what happened among participants in the study, but a comparator is needed to directly estimate how outcomes differ between treatment strategies. With no comparator described, even a complete response count would not supply a controlled treatment contrast. This distinction helps prevent descriptive observations from being mistaken for causal evidence.

The registry lists serious adverse-event terms and participant counts, which offer some safety information, while leaving important context unreported. Event attribution, timing, follow-up duration, and analysis-population details are not reported in the registry record. Readers therefore need to distinguish the presence of a recorded safety summary from a complete evaluation of risk.

The record also shows why reporting the analysis plan and missing-data handling matters. Without these details, it is difficult to know how endpoint assessments, incomplete observations, or multiple outcomes were handled. These are not merely technical details: they determine what population an estimate describes and how much confidence can be placed in it.

Statistically, this record is informative about the limits of what can be concluded from a study description alone. It gives enough information to identify the broad design and endpoint, but not enough to evaluate the primary result. Clear reporting of estimates, uncertainty, analysis populations, and study conduct is necessary for readers to move from a stated research question to an evidence-based interpretation.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most consequential limitation of the registry record is that it does not report the primary objective-response count or any analysis results. Consequently, response cannot be quantified, and its statistical precision cannot be evaluated. The record also does not report the number of participants assessed at 12 months or how missing or unevaluable imaging was handled.

The study is listed as single group, with allocation not applicable and no masking. No comparator is described, so the record cannot support a direct comparative estimate. The registry does not report whether imaging was reviewed independently, how response assessments were organized, or whether other steps were taken to limit assessment bias.

Further clinical and conduct details are not reported in the registry record. These include more specific eligibility criteria and participant characteristics, the reason for termination, treatment adherence, dose details beyond escalation to the maximum tolerated dose, and the analysis population. The registry does not state the statistical analysis plan, whether any interim analyses occurred, or how missing outcome information was addressed.

The safety summaries have their own limits. Event counts and terms are listed, but the record does not report event timing, duration, severity grading, recurrence, attribution, or the safety follow-up period. It does not describe the method used to code or review adverse events. As a result, the listed counts do not provide a full account of the clinical context or a causal comparison.

The start date, primary completion date, and terminated status are recorded, but the record does not explain the history leading to termination or provide an investigator’s final interpretation. These limitations mean that the registry entry can describe some features of the study but cannot establish its efficacy findings or provide a complete assessment of benefit and harm.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Antineoplaston Therapy in Treating Patients With Ependymoma — NCT00003479.
• Registry record last updated 2022-02-23; status last verified 2022-02.
• Results first posted 2017-02-17.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes a phase II, single-group study of antineoplaston therapy, Atengenal plus Astugenal, in patients with ependymoma. Enrollment is listed as 9; the study is recorded as terminated, with no masking and allocation not applicable. The intervention is described as intravenous infusion every four hours for at least 12 months, with dose increases until the maximum tolerated dose was reached.

The primary endpoint was the number of participants with objective response at 12 months, assessed by MRI using Response Assessment in Neuro-Oncology criteria. Percentage of participants who survived is listed as a secondary outcome. The registry record does not report results for either outcome or any statistical analyses.

Safety summaries list serious and other adverse-event counts and serious-event terms with reported percentages. The record does not provide detailed event context or establish causation. With no comparator and no reported primary result, the posted information supports a description of study design and recorded safety summaries, but not an estimate of comparative efficacy.